Daktarin Oral Gel Special Precautions

It is advisable to monitor miconazole and phenytoin levels, if these 2 drugs are used concomitantly.
In patients using certain oral hypoglycemics such as sulfonylureas, an enhanced therapeutic effect leading to hypoglycemia may occur during concomitant treatment with miconazole and appropriate measures must be considered (see Interactions).
It is important to take into consideration the variability of the maturation of the swallowing function in infants.
Particularly in infants and young children (aged 6 months-2 years), caution is required, to ensure that the gel does not obstruct the throat. Hence, the gel is not to be applied to the back of the throat. Each dose is to be divided into smaller portions and applied into the mouth with a clean finger. Observe the patient for possible choking. Also due to the risk of choking, the gel must not be applied to the nipple of a breast-feeding woman for administration to an infant.
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with DAKTARIN Oral Gel (see Adverse Reactions). If a reaction suggesting sensitivity should occur, the treatment should be discontinued.
Serious skin reactions (e.g. Toxic epidermal necrolysis and Stevens-Johnson syndrome) have been reported in patients receiving DAKTARIN Oral Gel (see Adverse Reactions). It is recommended that patients be informed about the signs of serious skin reactions, and that use of DAKTARIN Oral Gel be discontinued at the first appearance of skin rash.
Effects on Ability to Drive and Use Machines: DAKTARIN Oral Gel does not affect alertness or driving ability.